What does genomic medicine mean for diverse populations?

Molecular Genetics and Genomic Medicine

Volumn 2, Issue 1, 2014, Pages 3-6

  Adeyemo, Adebowale ^a   Rotimi, Charles ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926382824     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.63     Document Type: Article

References (19)

1. Adeyemo, A., and C. Rotimi. 2010. Genetic variants associated with complex human diseases show wide variation across multiple populations. Public Health Genomics 13:72–79.
2. Carlson, C. S., T. C. Matise, K. E. North, C. A. Haiman, M. D. Fesinmeyer, S. Buyske, et al. 2013. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol. 11:e1001661.
3. Chen, R., E. Corona, M. Sikora, J. T. Dudley, A. A. Morgan, A. Moreno-Estrada, et al. 2012. Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. PLoS Genet. 8:e1002621.
4. Ge, D., J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna, T. J. Urban, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401.
5. Genovese, G., D. J. Friedman, M. D. Ross, L. Lecordier, P. Uzureau, B. I. Freedman, et al. 2010. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841–845.
6. Ginsburg, G. S., and H. F. Willard. 2009. Genomic and personalized medicine: foundations and applications. Transl. Res. 154:277–287.
7. Hindorff, L. A., P. Sethupathy, H. A. Junkins, E. M. Ramos, J. P. Mehta, F. S. Collins, et al. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106:9362–9367.
8. Li, J., L. Zhang, H. Zhou, M. Stoneking, and K. Tang. 2011. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum. Mol. Genet. 20:528–540.
9. Limdi, N. A., M. Wadelius, L. Cavallari, N. Eriksson, D. C. Crawford, M. T. Lee, et al. 2010. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:3827–3834.
10. McCarthy, M. I. 2008. Casting a wider net for diabetes susceptibility genes. Nat. Genet. 40:1039–1040.
11. Muenke, M. 2013. Individualized genomics and the future of translational medicine. Mol. Genet. Genomic Med. 1:1–3.
12. Need, A. C., and D. B. Goldstein. 2009. Next generation disparities in human genomics: concerns and remedies. Trends Genet. 25:489–494.
13. Ntzani, E. E., G. Liberopoulos, T. A. Manolio, and J. P. Ioannidis. 2012. Consistency of genome-wide associations across major ancestral groups. Hum. Genet. 1311057–1071.
14. Perera, M. A., L. H. Cavallari, N. A. Limdi, E. R. Gamazon, A. Konkashbaev, R. Daneshjou, et al. 2013. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382:790–796.
15. Ramos, E., A. Doumatey, A. G. Elkahloun, D. Shriner, H. Huang, G. Chen, et al. 2013. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J. doi:10.1038/tpj.2013.24. [Epub ahead of print].
16. Suarez-Kurtz, G., and M. R. Botton. 2013. Pharmacogenomics of warfarin in populations of African descent. Br. J. Clin. Pharmacol. 75:334–346.
17. Unoki, H., A. Takahashi, T. Kawaguchi, K. Hara, M. Horikoshi, G. Andersen, et al. 2008. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat. Genet. 40:1098-1102.
18. Yang, J. J., C. Cheng, M. Devidas, X. Cao, Y. Fan, D. Campana, et al. 2011. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43:237–241.
19. Yasuda, K., K. Miyake, Y. Horikawa, K. Hara, H. Osawa, H. Furuta, et al. 2008. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat. Genet. 40:1092–1097.